LAVIPHARM S.A. NA EO 1
Research LAVIPHARM S.A. NA EO 1 (BXA0) on Bullrun: market cap EUR 255.14M, P/E 49.8, dividend yield 1.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBXA0
- ExchangeF
- CountryGreece
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 255.14M
- P/E49.8
- Dividend yield1.3%
- Financial periodFY2024
- RevenueEUR 52.95M
- Revenue growth10.7%
- Net incomeEUR 8.98M
- Free cash flow-EUR 5.00M
- Gross margin47.4%
Valuation Snapshot
latest market cap is EUR 255.14M; P/E is 49.8; dividend yield is 1.3%.
About LAVIPHARM S.A. NA EO 1
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products.
Frequently asked questions
What is LAVIPHARM S.A. NA EO 1's market cap?
LAVIPHARM S.A. NA EO 1's market capitalization is EUR 255.14M.
What is LAVIPHARM S.A. NA EO 1's P/E ratio?
LAVIPHARM S.A. NA EO 1's price-to-earnings (P/E) ratio is 49.8.
Does LAVIPHARM S.A. NA EO 1 pay a dividend?
LAVIPHARM S.A. NA EO 1 has a dividend yield of 1.3%.
What does LAVIPHARM S.A. NA EO 1 do?
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally.